



GLOBAL JOURNAL OF MEDICAL RESEARCH: L

NUTRITION & FOOD SCIENCE

Volume 22 Issue 1 Version 1.0 Year 2022

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Effect of Obesity in Memory and Cognition

By Amina Khatun, Kuntal Ghosh, Shrabani Pradhan & Sudipta Chakrabarti

Abstract- Presently a day's obesity is one of the significant public issues worldwide among kids, teenagers, just as in grown-ups and older people. From the distinctive animal models and clinical trials, it was accounted that natural adequacy related to weight is connected with more regrettable memory function. Evidence recognizes obesity as a significant danger factor for the beginning and progression of a few neurological problems associated with metabolic dysfunction and inflammation, which are related to obesity are owing to consequences for the primarily cognitive impairment. Numerous studies suggest that obesity results in neurological diseases such as Parkinson's disease and Alzheimer's disease, which could be initiated by various metabolic alterations, related to CNS damage as well as cognitive loss or cognitive dysfunction. This review examined whether obesity is associated with cognitive function or cognitive decline and whether obesity confounds the relationship between obesity and cognitive decline. This review approach was employed, using PubMed, and the Google Scholar database. Worse memory function may directly be related to obesity with underlying mechanisms discussed here. However, it is uncertain whether adiposity, itself, is influencing cognitive changes and it drives the obesity-cognitive relationship.

Keywords: *obesity; alzheimer's disease; parkinson's disease; cognitive impairments.*

GJMR-L Classification: DDC Code: 616.15 LCC Code: RB145



EFFECT OF OBESITY IN MEMORY AND COGNITION

Strictly as per the compliance and regulations of:



RESEARCH | DIVERSITY | ETHICS

Effect of Obesity in Memory and Cognition

Amina Khatun ^a, Kuntal Ghosh ^a, Shrabani Pradhan ^b & Sudipta Chakrabarti ^c

Abstract- Presently a day's obesity is one of the significant public issues worldwide among kids, teenagers, just as in grown-ups and older people. From the distinctive animal models and clinical trials, it was accounted that natural adequacy related to weight is connected with more regrettable memory function. Evidence recognizes obesity as a significant danger factor for the beginning and progression of a few neurological problems associated with metabolic dysfunction and inflammation, which are related to obesity are owing to consequences for the primarily cognitive impairment. Numerous studies suggest that obesity results in neurological diseases such as Parkinson's disease and Alzheimer's disease, which could be initiated by various metabolic alterations, related to CNS damage as well as cognitive loss or cognitive dysfunction. This review examined whether obesity is associated with cognitive function or cognitive decline and whether obesity confounds the relationship between obesity and cognitive decline. This review approach was employed, using PubMed, and the Google Scholar database. Worse memory function may directly be related to obesity with underlying mechanisms discussed here. However, it is uncertain whether adiposity, itself, is influencing cognitive changes and it drives the obesity-cognitive relationship.

Keywords: obesity; alzheimer's disease; parkinson's disease; cognitive impairments.

I. INTRODUCTION

Obesity is a roaring global concern with a sprouting predominance in children (Ogden, Carroll, Kit, & Flegal, 2014), adolescents, and older people on the earth, especially in a developing country. The number of obese people also has expanded day by day in an epidemic manner throughout the last decade. It was accounted that the prevalence rate of obesity and central obesity varies from 11.8% to 31.3% and 16.9%–36.3%, respectively according to ICMR-INDIAB study 2015, (Ahirwar & Mondal, 2019). Obesity is characterized by the exorbitant gathering of fat, especially adipose tissues, which can adversely influence well-being by expanding the expression of pro-inflammatory markers(Huang, Zhang, & Chen, 2016). Due to the accumulation of excessive adipocytes, various health consequences such as increased heart disease, hypertension, diabetes, inactivity, inflammation, genetic alteration, stroke, and cancer (Aronne, 2001) occur. Some of these

Author a: Department of Biological Sciences, Midnapore City College, Kuturiya, Bhadutala, Paschim Medinipur, West Bengal, India.

Author b: Department of Paramedical Sciences, Midnapore City College, Kuturiya, Bhadutala, Paschim Medinipur, West Bengal, India.

Corresponding Author c: Department of Biological Sciences, Midnapore City College, Kuturiya, Bhadutala, Paschim Medinipur, West Bengal, India. e-mail: sduiptadna@gmail.com

medical comorbidities are associated with adverse cognitive effects (Biessels, Deary, & Ryan, 2008). There is a strong correlation between obesity and neurodegenerative diseases, suggesting that obesity might affect the central nervous system, causing neurodegeneration and cognitive decline, as well as causing brain damage (Ashrafiyan, Harling, Darzi, & Athanasiou, 2013). Neurodegenerative disease (ND) is a significant reason for inability, morbidity, and diminished personal satisfaction, establishing the basis for 12 % of human death internationally (Erkkinen, Kim, & Geschwind, 2018). Investigations have shown that individuals who experience the ill effects of midlife obesity (estimated by BMI) have an expanded danger to building Alzheimer's Disease (AD) and Parkinson's Disease (PD) (Profenno, Porsteinsson, & Faraone, 2010). The role of obesity in memory and cognitive decline has been reviewed in this article.

II. EFFECT OF OBESITY ON BRAIN STRUCTURE AND COGNITIVE CAPACITY

a) Brain Structure

Structure alteration in neural architecture due to obesity has been recently reported. For instance, raised BMI is connected to diminished cerebrum volume (Ward, Carlsson, Trivedi, Sager, & Johnson, 2005), the autonomy of age, and morbidity (Gunstad et al., 2008). Expanded BMI is connected with gray matter decay in some specific parts of the brain (Shefer, Marcus, & Stern, 2013), and decreased uprightness of white matter of the brain (Verstynen et al., 2012). Middle-age must be the most critical period for brain aging and at that time, vulnerability to obesity is particularly acute compared with later life (Ronan et al., 2016), and the starting of middle-age, there has been identified white matter atrophy (Fotenos, Snyder, Girton, Morris, & Buckner, 2005) in the brain. Recently, Thompson et al. (2020) conducted a meta-analysis where the connection between obesity ($BMI > 30 \text{ kg/m}^2$) and brain structure of 6420 members was studied. Obesity has been shown to be associated with brain structure abnormalities, including a lowered temporal-frontal thickness. Cortical thinning of the brain might be related to decreased microstructural integrity in white matter tracts in obese teenagers (Yau et al., 2014). Further, obesity decreases practical movement in cortical regions that are associated with episodic memory (hippocampus, dorsolateral prefrontal cortex, and angular gyrus) (Cheke, Bonnici, Clayton, & Simons, 2017). Obesity also causes an increase in the amount of glycerol,



hormones, cytokines, and pro-inflammatory substances involved in developing insulin resistance (Al-Goblan, Al-Alfi, & Khan, 2014). The hippocampus might be especially helpless against the adverse consequences of abnormal glucose tolerance and insulin resistance comparative with other cerebrum districts, a suggestion supported by neurological, structural research associating type 2 diabetes and impaired glucose tolerance (IGT) with hippocampal atrophy (Bruehl et al., 2009; Gold & Shadlen, 2007; Korf, White, Scheltens, & Launer, 2006). Expanded development of harmful glycation end product results in hyperglycemia and type 2 diabetes (Roriz-Filho et al., 2009), this could result in hippocampal volume loss, especially given that the hippocampus is profoundly defenseless against other metabolic affronts (McEwen, 1997; Stranahan et al., 2008). Hippocampus has a high co-restriction of insulin and cortisol receptors (Jacobson & Sapolsky, 1991). It has been guessed that persistently raised corticosteroids related to type 2 diabetes could modify synaptic plasticity and *explicit neurogenesis* in the hippocampus (Magariños & McEwen, 2000). The conceivable clarification could be that peripheral insulin resistance results in expanded hepatic lipid production, especially in ceramides, a product from unsaturated fats and sphingosine and is known to have lipid solvent properties (Tong & de la Monte, 2009). A few studies have shown that ceramide promotes brain insulin resistance through an impaired brain insulin pathway (Arboleda, Morales, Benítez, & Arboleda, 2009), and results in neurodegeneration as a consequence (Arboleda et al., 2009; Sartorius et al., 2014; Tong & de la Monte, 2009). Even though there was no proof that ceramide straightforwardly results in blood-brain barrier disturbance, it is conceivable that a lot of ceramides under obese conditions might be one of the dangerous elements to cause the interruption of the blood-brain barrier. In this way, the blood-brain barrier can be crossed (Fig. 1).

b) Cognitive and memory impairment

After different longitudinal and cross-sectional investigations, researchers considered that obesity in early adulthood or middle age could extend one's risk of later-life cognitive inability. People who had higher BMI in midlife displayed shortages in an assortment of mental spaces, including long-and short memory, psychomotor speed, verbal capacity, and spatial capacity, this led to more fast destruction of cognition (Hassing, Dahl, Pedersen, & Johansson, 2010). An increased BMI, as well as increased energy metabolites (Roriz-Filho et al., 2009), result in worse memory performance by causing hypertonicity and neuroinflammation (Gonzales et al., 2012). Numerous studies have shown that the "Western diet", which is high in saturated fats and simple sugars, impairs learning and memory in people who are obese (Beilharz,

Maniam, & Morris, 2015; Loprinzi, Frith, Edwards, Sng, & Ashpole, 2018). It is associated with decreased neurogenesis and increased inflammatory responses. As it is also shown, diet plays a vital role in such memory impairments, as opposed to being caused by adipose changes, and the brain's working memory and negative outcome learning capacity are hampered due to adaptations in the dopamine system due to obesity-induced overeating. (Coppin, Nolan-Poupart, Jones-Gotman, & Small, 2014).

BBB is mainly made up of endothelial cells. However, obesity is a cause of endothelial brokenness, adding to BBB deterioration through some mechanisms (Wardlaw et al., 2013). This results obesity-related cognitive impairments, initiates neuroinflammation and neurodegeneration. Disturbance in the tight junction of endothelium breakdown the BBB (Zlokovic, 2008) proposes that obesity might trigger tight junction interruption prompting BBB breakdown. The disruption of BBB by lipid-like substances results in microglial activation, decreased endothelial tight junction and protein articulation (Shigemoto-Mogami, Hoshikawa, & Sato, 2018; Sumi et al., 2010), ultimately leading to persistence neuroinflammation (Dalvi et al., 2017; Thaler et al., 2012) and cognitive dysfunction (Kahn & Flier, 2000). In like manner, (Bocarsly et al., 2015) announced that obesity prompted decreases in dendritic spines and led to cognitive decline. It has been shown from different findings that obesity is associated with systemic and central inflammation (Gregor & Hotamisligil, 2011; Miller & Spencer, 2014) and is always hindering memory and cognition by stimulating the production of pro-inflammatory cytokines and adipokines that lead to insulin resistance (Su et al., 2017). De Souza and partners found that high-fat diets or obesity raises the pro-inflammatory cytokines and the pro-inflammatory transcription factor NF κ B in the hypothalamus (De Souza et al., 2005). The hippocampus, a significant area in cognitive preparing, learning, and memory, might be especially defenseless against inflammation in obesity, with raised TNF- α and ionized calcium-binding connector particle 1 (Iba1; microglial marker) (Jeon et al., 2012). Hence, this concluded that systemic inflammation and obesity have been recognized as the leading cause of cerebral white matter injuries and cognitive brokenness (T Den Heijer et al., 2005; Viscogliosi, Donfrancesco, Palmieri, & Giampaoli, 2017). In addition, higher plasma levels of interleukin (IL)-12 and 6 are connected to diminished speed in handling data and a quicker pace of cognitive decay (Marioni et al., 2010; Schram et al., 2007; Trollor et al., 2012). Hypertension expands one's danger of being diagnosed to have mild cognitive impairment (MCI) (Reitz, Tang, Manly, Mayeux, & Luchsinger, 2007). It predicts the degree of weakness seen in these people (Goldstein, Levey, & Steenland, 2013). Obesity-induced hypertension in midlife is conversely identified with

execution on an assortment of cognitive tests, for example, those verbal surveying memory and executive function during obesity (M. Elias, Elias, Sullivan, Wolf, & D'agostino, 2003; Launer, Masaki, Petrovitch, Foley, & Havlik, 1995). Past research has shown that mitochondria assume a crucial part in cerebrum synaptic transmission and age-related intellectual capacity (A. Cheng, Hou, & Mattson, 2010; Hara et al., 2014; Mattson, Gleichmann, & Cheng, 2008; Raefsky & Mattson, 2017). That study suggested that changes in the shape of mitochondria in presynaptic neurons affected synaptic transmission. Additionally, apoptosomes are formed that activate the caspase cascades and subsequently trigger cell death(Cain, Bratton, & Cohen, 2002). Research has shown increased level of pro-apoptotic proteins (Bax and Bad) in brain tissue from rodents with insulin resistance caused by mitochondrial impairment, along with reduced levels of anti-apoptotic proteins (Bcl-2) (Nuzzo et al., 2015; Sa-Nguanmoo et al., 2017; Sa-Nguanmoo et al., 2016). An increment in pro-apoptotic proteins can prompt cytochrome C release, bringing about cerebrum apoptosis (Gómez-Crisóstomo, López-Marure, Zapata, Zazueta, & Martínez-Abundis, 2013). Also, apoptotic-mediated neuronal passing has been known to be one fundamental component for intellectual weakness and other neurodegenerative infections and cognitive loss (Ghavami et al., 2014).

III. OBESITY AND DEMENTIA

As populaces age, intellectual problems, including dementias, become more normal. The most common form of dementia is Alzheimer's disease (AD), representing somewhere in the range of half and 70% of all dementias. Ongoing efficient reviews and meta-examinations uncover an unpredictable connection between obesity and the possibility of dementias (Anstey, Cherbuin, Budge, & Young, 2011; Beydoun et al., 2011; Gorospe & Dave, 2007). The conviction of dementia being a solitary memory-related confusion of Alzheimer's disease (AD) has tremendously congested. The present comprehension of dementia is a complete loss of memory with diminished mental and scholarly execution because of damaged synapses. The current existing research on BMI and AD is conflicting and consolidating the consequences of many investigations that exhibited a lot of conflicting data. A meta-examination done on 16 articles covering 15 planned investigations showed that underweight, overweight, and obesity in midlife is related to an expanded danger of dementia when contrasted with having normal weight or BMI. Having a raised BMI in midlife altogether expands the danger of dementia perhaps because of expanded inflammation, higher cytokine, and hormone created by fat tissues (Skoog & Gustafson, 2003). Having an expanded BMI can likewise be related to

countless morbidities, for example, insulin opposition prompting diabetes, elevated cholesterol, hypertension, and cardiovascular infection (Naderali, Ratcliffe, & Dale, 2009). The vascular impacts may likewise play a part in advancing a quickly developing disease of late-life, Alzheimer's pathology. Additionally, the variables mentioned above and the higher BMI is link with the changes in cerebrum structure, white matter changes, blood-brain obstruction aggravations, and the age-related administrative changes in protein, carbohydrate, and lipid digestion that might trigger dementia pathology. The persistent overconsumption of food sources wealthy in carbohydrates and lipids in obesity can influence insulin emission and fundamentally affects cerebral glucose digestion. The normal intracellular components in type 2 Diabetes Mellitus and AD incorporate variant redox guidelines, oxidative pressure, and dynamic incendiary cycles bringing about disabled insulin emission and signaling pathways(Verdile et al., 2015). Studies have shown that central insulin organization may be powerful in helping people with Alzheimer's to perform cognitively (Claxton et al., 2015; Freiherr et al., 2013; Haj-Ali, Mohaddes, & Babri, 2009). Further evidence suggests insulin may influence AD-related proteins (e.g., APP and tau) and contribute to the progression of AD pathology and cognitive impairment (Ferreira, Clarke, Bomfim, & De Felice, 2014; Steculorum, Solas, & Brüning, 2014; Umegaki, 2014). The T2DM has a particularly damaging effect on the hippocampus - a part of the brain crucial for memory and learning functions (Bruehl et al., 2009; Tom den Heijer et al., 2003; Gold & Shadlen, 2007; Korf et al., 2006). Though diabetes is not just a danger factor for mild cognitive impairment (MCI) and Alzheimer's disorder yet in addition to some other kinds of dementia (G. Cheng, Huang, Deng, & Wang, 2012). Obesity can likewise initiate endothelial brokenness and cause cerebral hypoperfusion and improve the creation of β -amyloid that will general, diminish endothelial capacity further, making an endless loop prompting pathogenic changes of AD. This endothelial brokenness is because of a diminished combination and activities of nitric oxide (NO) from the endothelium and expanding the development of oxidative pressure. Increasing levels of deviated dimethylarginine inhibit NO synthase activity, resulting in cerebral hypoperfusion and mental and neurodegenerative changes in AD (Toda, Ayajiki, & Okamura, 2014). In addition to the A β and Tau proteins causing AD, many factors are also a contributing factor to this disease (Alves, Correia, Miguel, Alegria, & Bugalho, 2012) including mitochondrial impairments, ROS generation, oxidative damage, proinflammatory responses, energy utilization impairments, and failure in various neurotransmission systems(Cai, Zhao, & Ratka, 2011; Ferrer et al., 2012). The gut-brain axis, also known as the gut-microbiota interaction, has also been suggested to be important in the utilization of high fat



diets and other imbalanced eating plans that hinder perception (Solas, Milagro, Ramírez, & Martínez, 2017). Notably, cognitive execution and markers of cerebrum decay like whole brain and hippocampal volumes are amazing indicators of intellectual decrease and dementia in everyone (Amiya et al., 2005; M. F. Elias et al., 2000; Jack et al., 2005). In this manner, obesity-related degradation might intensify the danger for dementia and a cognitive decrease by synergistically associating with the maturing system. Predictable with this idea, higher BMI is associated with cerebrum degradation in patients determined to have AD (Abilés et al., 2010). Besides, there is proof that midlife obesity is related to an expanded pace of aggregate and hippocampal brain degradation and cognitive decrease ten years after the fact (Debette et al., 2011) and finally, cases of neurodegenerative disease. AD and PD are two main neurodegenerative diseases characterized by

the accumulation of abnormal protein in the brain, results in a neuronal loss (Gaeta & Hider, 2005) and causes cognitive impairment.

IV. SUMMARY AND CONCLUSION

As a result of the systematic frame introduced in this review, we can now understand how obesity leads to brain changes that can result in cognitive impairment. As in addition to inflammation, hyperinsulinemia/insulin resistance, interruption of oxidative stress, and neurodegenerative diseases, obesity has been associated with cognitive impairment. It can therefore be concluded that obesity-induced structural changes in the brain, impaired mitochondrial function, insulin resistance and blood-brain barrier are major contributors to memory impairment.




Fig.1: Systemic diagram of obesity-induced cognitive decline.

Abbreviations: AD (Alzheimer's Disease), PD (Parkinson's Disease), ND (neurodegenerative disease), BMI (basal metabolic rate), BBB (blood-brain barrier), T2DM (Type 2 diabetes mellitus), MCI (mild cognitive impairment), NF κ B (nuclear factor κ B), TNF- α (Tumour Necrosis Factor- α), IL- 12 (interleukin-12), A β (amyloid β).

REFERENCES RÉFÉRENCES REFERENCIAS

1. Abilés, V., Rodríguez-Ruiz, S., Abilés, J., Mellado, C., García, A., De La Cruz, A. P., & Fernández-

Santaella, M. C. (2010). Psychological characteristics of morbidly obese candidates for bariatric surgery. *Obesity surgery*, 20(2), 161-167.

2. Ahirwar, R., & Mondal, P. R. (2019). Prevalence of obesity in India: A systematic review. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 13(1), 318-321.
3. Al-Goblan, A. S., Al-Alfi, M. A., & Khan, M. Z. (2014). The mechanism linking diabetes mellitus and obesity. *Diabetes, metabolic syndrome, and obesity: targets and therapy*, 7, 587.

4. Alves, L., Correia, A. S. A., Miguel, R., Alegria, P., & Bugalho, P. (2012). Alzheimer's disease: a clinical practice-oriented review. *Frontiers in neurology*, 3, 63.
5. Amiya, N., Amano, M., Takahashi, A., Yamanome, T., Kawauchi, H., & Yamamori, K. (2005). Effects of tank color on melanin-concentrating hormone levels in the brain, pituitary gland, and plasma of the barf in flounder as revealed by a newly developed time-resolved fluoroimmunoassay. *General and Comparative Endocrinology*, 143(3), 251-256.
6. Anstey, K., Cherbuin, N., Budge, M., & Young, J. (2011). Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. *Obesity reviews*, 12(5), e426-e437.
7. Arboleda, G., Morales, L. C., Benítez, B., & Arboleda, H. (2009). Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration. *Brain research reviews*, 59(2), 333-346.
8. Aronne, L. J. (2001). Epidemiology, morbidity, and treatment of overweight and obesity. *Journal of Clinical Psychiatry*, 62, 13-22.
9. Ashrafi, H., Harling, L., Darzi, A., & Athanasiou, T. (2013). Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions? *Metabolic brain disease*, 28(3), 341-353.
10. Beilharz, J. E., Maniam, J., & Morris, M. J. (2015). Diet-induced cognitive deficits: the role of fat and sugar, potential mechanisms and nutritional interventions. *Nutrients*, 7(8), 6719-6738.
11. Beydoun, M. A., Beason-Held, L. L., Kitner-Triolo, M. H., Beydoun, H. A., Ferrucci, L., Resnick, S. M., & Zonderman, A. B. (2011). Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. *J Epidemiol Community Health*, 65(11), 949-957.
12. Biessels, G. J., Deary, I. J., & Ryan, C. M. (2008). Cognition and diabetes: a lifespan perspective. *The Lancet Neurology*, 7(2), 184-190.
13. Bocarsly, M. E., Fasolino, M., Kane, G. A., LaMarca, E. A., Kirschen, G. W., Karatsoreos, I. N., . . . Gould, E. (2015). Obesity diminishes synaptic markers, alters microglial morphology, and impairs cognitive function. *Proceedings of the National Academy of Sciences*, 112(51), 15731-15736.
14. Bruehl, H., Wolf, O. T., Sweat, V., Tarsi, A., Richardson, S., & Convit, A. (2009). Modifiers of cognitive function and brain structure in middle-aged and elderly individuals with type 2 diabetes mellitus. *Brain research*, 1280, 186-194.
15. Cai, Z., Zhao, B., & Ratka, A. (2011). Oxidative stress and β -amyloid protein in Alzheimer's disease. *Neuromolecular medicine*, 13(4), 223-250.
16. Cain, K., Bratton, S. B., & Cohen, G. M. (2002). The Apaf-1 apoptosome: a large caspase-activating complex. *Biochimie*, 84(2-3), 203-214.
17. Cheke, L. G., Bonnici, H. M., Clayton, N. S., & Simons, J. S. (2017). Obesity and insulin resistance are associated with reduced activity in core memory regions of the brain. *Neuropsychologia*, 96, 137-149.
18. Cheng, A., Hou, Y., & Mattson, M. P. (2010). Mitochondria and neuroplasticity. *ASN neuro*, 2(5), AN20100019.
19. Cheng, G., Huang, C., Deng, H., & Wang, H. (2012). Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. *Internal medicine journal*, 42(5), 484-491.
20. Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., . . . Craft, S. (2015). Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. *Journal of Alzheimer's Disease*, 44(3), 897-906.
21. Coppin, G., Nolan-Poupart, S., Jones-Gotman, M., & Small, D. M. (2014). Working memory and reward association learning impairments in obesity. *Neuropsychologia*, 65, 146-155.
22. Dalvi, P., Chalmers, J., Luo, V., Han, D.-Y., Wellhauser, L., Liu, Y., . . . Wheeler, M. (2017). High fat induces acute and chronic inflammation in the hypothalamus: effect of high-fat diet, palmitate and TNF- α on appetite-regulating NPY neurons. *International journal of obesity*, 41(1), 149-158.
23. De Souza, C. T., Araujo, E. P., Bordin, S., Ashimine, R., Zollner, R. L., Boschero, A. C., . . . Velloso, L. c. A. (2005). Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. *Endocrinology*, 146(10), 4192-4199.
24. Debette, S., Seshadri, S., Beiser, A., Au, R., Himali, J., Palumbo, C., . . . DeCarli, C. (2011). Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology*, 77(5), 461-468.
25. Den Heijer, T., Launer, L., Prins, N., Van Dijk, E., Vermeer, S., Hofman, A., . . . Breteler, M. (2005). Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. *Neurology*, 64(2), 263-267.
26. den Heijer, T., Vermeer, S., Van Dijk, E., Prins, N., Koudstaal, P., Hofman, A., & Breteler, M. (2003). Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. *Diabetologia*, 46(12), 1604-1610.
27. Elias, M., Elias, P., Sullivan, L., Wolf, P., & D'agostino, R. (2003). Lower cognitive function in the presence of obesity and hypertension: the

Framingham heart study. *International journal of obesity*, 27(2), 260-268.

28. Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000). The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham Cohort. *Archives of neurology*, 57(6), 808-813.

29. Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018). Clinical neurology and epidemiology of the major neurodegenerative diseases. *Cold Spring Harbor perspectives in biology*, 10(4), a033118.

30. Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & De Felice, F. G. (2014). Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. *Alzheimer's & dementia*, 10(1), S76-S83.

31. Ferrer, I., López-Gonzalez, I., Carmona, M., Dalfó, E., Pujol, A., & Martínez, A. (2012). Neurochemistry and the non-motor aspects of PD. *Neurobiology of disease*, 46(3), 508-526.

32. Fotenos, A. F., Snyder, A., Girton, L., Morris, J., & Buckner, R. (2005). Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. *Neurology*, 64(6), 1032-1039.

33. Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., . . . Benedict, C. (2013). Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. *CNS drugs*, 27(7), 505-514.

34. Gaeta, A., & Hider, R. C. (2005). The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. *British journal of pharmacology*, 146(8), 1041-1059.

35. Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., . . . Kashani, H. H. (2014). Autophagy and apoptosis dysfunction in neurodegenerative disorders. *Progress in neurobiology*, 112, 24-49.

36. Gold, J. I., & Shadlen, M. N. (2007). The neural basis of decision making. *Annu. Rev. Neurosci.*, 30, 535-574.

37. Goldstein, F. C., Levey, A. I., & Steenland, N. K. (2013). High blood pressure and cognitive decline in mild cognitive impairment. *Journal of the American Geriatrics Society*, 61(1), 67-73.

38. Gómez-Crisóstomo, N. P., López-Marure, R., Zapata, E., Zazueta, C., & Martínez-Abundis, E. (2013). Bax induces cytochrome c release by multiple mechanisms in mitochondria from MCF7 cells. *Journal of bioenergetics and biomembranes*, 45(5), 441-448.

39. Gonzales, M. M., Takashi, T., Eagan, D. E., Tanaka, H., Vagharia, M., & Haley, A. P. (2012). Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations. *Psychosomatic medicine*, 74(7), 691.

40. Gorospe, E. C., & Dave, J. K. (2007). The risk of dementia with increased body mass index. *Age and ageing*, 36(1), 23-29.

41. Gregor, M. F., & Hotamisligil, G. S. (2011). Inflammatory mechanisms in obesity. *Annual review of immunology*, 29, 415-445.

42. Gunstad, J., Paul, R. H., Cohen, R. A., Tate, D. F., Spitznagel, M. B., Grieve, S., & Gordon, E. (2008). Relationship between body mass index and brain volume in healthy adults. *International Journal of Neuroscience*, 118(11), 1582-1593.

43. Haj-Ali, V., Mohaddes, G., & Babri, S. (2009). Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. *Behavioral neuroscience*, 123(6), 1309.

44. Hara, Y., Yuk, F., Puri, R., Janssen, W. G., Rapp, P. R., & Morrison, J. H. (2014). Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment. *Proceedings of the National Academy of Sciences*, 111(1), 486-491.

45. Hassing, L. B., Dahl, A. K., Pedersen, N. L., & Johansson, B. (2010). Overweight in midlife is related to lower cognitive function 30 years later: a prospective study with longitudinal assessments. *Dementia and geriatric cognitive disorders*, 29(6), 543-552.

46. Huang, W. J., Zhang, X., & Chen, W. W. (2016). Role of oxidative stress in Alzheimer's disease. *Biomedical reports*, 4(5), 519-522.

47. Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., . . . Antel, J. P. (2005). TLR signaling tailors innate immune responses in human microglia and astrocytes. *The Journal of Immunology*, 175(7), 4320-4330.

48. Jacobson, L., & Sapolsky, R. (1991). The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. *Endocrine reviews*, 12(2), 118-134.

49. Jeon, B. T., Jeong, E. A., Shin, H. J., Lee, Y., Lee, D. H., Kim, H. J., . . . Roh, G. S. (2012). Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. *Diabetes*, 61(6), 1444-1454.

50. Kahn, B. B., & Flier, J. S. (2000). Obesity and insulin resistance. *The Journal of clinical investigation*, 106(4), 473-481.

51. Korf, E. S., White, L. R., Scheltens, P., & Launer, L. J. (2006). Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. *Diabetes care*, 29(10), 2268-2274.

52. Launer, L. J., Masaki, K., Petrovitch, H., Foley, D., & Havlik, R. J. (1995). The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. *Jama*, 274(23), 1846-1851.

53. Loprinzi, P. D., Frith, E., Edwards, M. K., Sng, E., & Ashpole, N. (2018). The effects of exercise on memory function among young to middle-aged adults: systematic review and recommendations for future research. *American Journal of Health Promotion*, 32(3), 691-704.

54. Magariños, A. M., & McEwen, B. S. (2000). Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. *Proceedings of the National Academy of Sciences*, 97(20), 11056-11061.

55. Marioni, R. E., Strachan, M. W., Reynolds, R. M., Lowe, G. D., Mitchell, R. J., Fowkes, F. G. R., . . . Rumley, A. (2010). Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. *Diabetes*, 59(3), 710-713.

56. Mattson, M. P., Gleichmann, M., & Cheng, A. (2008). Mitochondria in neuroplasticity and neurological disorders. *Neuron*, 60(5), 748-766.

57. McEwen, B. (1997). Possible mechanisms for atrophy of the human hippocampus. *Molecular psychiatry*, 2(3), 255-262.

58. Miller, A. A., & Spencer, S. J. (2014). Obesity and neuroinflammation: a pathway to cognitive impairment. *Brain, behavior, and immunity*, 42, 10-21.

59. Naderali, E. K., Ratcliffe, S. H., & Dale, M. C. (2009). Obesity and Alzheimer's disease: a link between body weight and cognitive function in old age. *American Journal of Alzheimer's Disease & Other Dementias®*, 24(6), 445-449.

60. Nuzzo, D., Picone, P., Baldassano, S., Caruana, L., Messina, E., Marino Gammazza, A., . . . Di Carlo, M. (2015). Insulin resistance as common molecular denominator linking obesity to Alzheimer's disease. *Current Alzheimer Research*, 12(8), 723-735.

61. Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014). Prevalence of childhood and adult obesity in the United States, 2011-2012. *Jama*, 311(8), 806-814.

62. Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010). Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. *Biological psychiatry*, 67(6), 505-512.

63. Raefsky, S. M., & Mattson, M. P. (2017). Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance. *Free Radical Biology and Medicine*, 102, 203-216.

64. Reitz, C., Tang, M.-X., Manly, J., Mayeux, R., & Luchsinger, J. A. (2007). Hypertension and the risk of mild cognitive impairment. *Archives of neurology*, 64(12), 1734-1740.

65. Ronan, L., Alexander-Bloch, A. F., Wagstyl, K., Farooqi, S., Brayne, C., Tyler, L. K., & Fletcher, P. C. (2016). Obesity-associated with increased brain age from midlife. *Neurobiology of aging*, 47, 63-70.

66. Roriz-Filho, J. S., Sá-Roriz, T. M., Rosset, I., Camozzato, A. L., Santos, A. C., Chaves, M. L., . . . Roriz-Cruz, M. (2009). (Pre) diabetes, brain aging, and cognition. *Biochimica et biophysica acta (BBA)-molecular basis of disease*, 1792(5), 432-443.

67. Sa-Nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayarakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017). SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. *Toxicology and applied pharmacology*, 333, 43-50.

68. Sa-Nguanmoo, P., Tanajak, P., Kerdphoo, S., Satjaritanun, P., Wang, X., Liang, G., . . . Chattipakorn, N. (2016). FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function, and cell apoptosis in obese-insulin-resistant male rats. *Hormones and behavior*, 85, 86-95.

69. Sartorius, T., Peter, A., Schulz, N., Drescher, A., Bergheim, I., Machann, J., . . . Weigert, C. (2014). Cinnamon extract improves insulin sensitivity in the brain and lowers liver fat in mouse models of obesity. *PloS one*, 9(3), e92358.

70. Schram, M. T., Euser, S. M., De Craen, A. J., Witteman, J. C., Frölich, M., Hofman, A., . . . Westendorp, R. G. (2007). Systemic markers of inflammation and cognitive decline in old age. *Journal of the American Geriatrics Society*, 55(5), 708-716.

71. Shefer, G., Marcus, Y., & Stern, N. (2013). Is obesity a brain disease? *Neuroscience & Biobehavioral Reviews*, 37(10), 2489-2503.

72. Shigemoto-Mogami, Y., Hoshikawa, K., & Sato, K. (2018). Activated microglia disrupt the blood-brain barrier and induce chemokines and cytokines in a rat *in vitro* model. *Frontiers in cellular neuroscience*, 12, 494.

73. Skoog, I., & Gustafson, D. (2003). Hypertension, hypertension-clustering factors, and Alzheimer's disease. *Neurological research*, 25(6), 675-680.

74. Solas, M., Milagro, F. I., Ramírez, M. J., & Martínez, J. A. (2017). Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. *Current opinion in pharmacology*, 37, 87-92.

75. Steculorum, S. M., Solas, M., & Brüning, J. C. (2014). The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. *Alzheimer's & dementia*, 10, S3-S11.

76. Stranahan, A. M., Norman, E. D., Lee, K., Cutler, R. G., Telljohann, R. S., Egan, J. M., & Mattson, M. P. (2008). Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in



middle-aged rats. *Hippocampus*, 18(11), 1085-1088.

77. Su, F., Shu, H., Ye, Q., Wang, Z., Xie, C., Yuan, B., . . . Bai, F. (2017). Brain insulin resistance deteriorates cognition by altering the topological features of brain networks. *NeuroImage: Clinical*, 13, 280-287.

78. Sumi, N., Nishioku, T., Takata, F., Matsumoto, J., Watanabe, T., Shuto, H., . . . Kataoka, Y. (2010). Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. *Cellular and molecular neurobiology*, 30(2), 247-253.

79. Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., . . . Maravilla, K. R. (2012). Obesity is associated with hypothalamic injury in rodents and humans. *The Journal of clinical investigation*, 122(1), 153-162.

80. Thompson, P. M., Jahanshad, N., Ching, C. R., Salminen, L. E., Thomopoulos, S. I., Bright, J., . . . Bruun, W. B. (2020). ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. *Translational psychiatry*, 10(1), 1-28.

81. Toda, N., Ayajiki, K., & Okamura, T. (2014). Obesity-induced cerebral hypoperfusion derived from endothelial dysfunction: one of the risk factors for Alzheimer's disease. *Current Alzheimer Research*, 11(8), 733-744.

82. Tong, M., & de la Monte, S. M. (2009). Mechanisms of ceramide-mediated neurodegeneration. *Journal of Alzheimer's Disease*, 16(4), 705-714.

83. Trollor, J. N., Smith, E., Agars, E., Kuan, S. A., Baune, B. T., Campbell, L., . . . Kochan, N. A. (2012). The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study. *Age*, 34(5), 1295-1308.

84. Umegaki, H. (2014). Type 2 diabetes as a risk factor for cognitive impairment: current insights. *Clinical interventions in aging*, 9, 1011.

85. Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., . . . Newsholme, P. (2015). Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease. *Mediators of inflammation*, 2015.

86. Verstynen, T. D., Lynch, B., Miller, D. L., Voss, M. W., Prakash, R. S., Chaddock, L., . . . Wojcicki, T. R. (2012). Caudate nucleus volume mediates the link between cardiorespiratory fitness and cognitive flexibility in older adults. *Journal of aging research*, 2012.

87. Viscogliosi, G., Donfrancesco, C., Palmieri, L., & Giampaoli, S. (2017). The metabolic syndrome and 10-year cognitive and functional decline in very old men. A population-based study. *Archives of gerontology and geriatrics*, 70, 62-66.

88. Ward, M. A., Carlsson, C. M., Trivedi, M. A., Sager, M. A., & Johnson, S. C. (2005). The effect of body mass index on global brain volume in middle-aged adults: a cross-sectional study. *BMC neurology*, 5(1), 1-7.

89. Wardlaw, J. M., Doubal, F. N., Valdes-Hernandez, M., Wang, X., Chappell, F. M., Shuler, K., . . . Dennis, M. S. (2013). Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease. *Stroke*, 44(2), 525-527.

90. Yau, S. Y., Li, A., Hoo, R. L., Ching, Y. P., Christie, B. R., Lee, T. M., . . . So, K.-F. (2014). Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin. *Proceedings of the National Academy of Sciences*, 111(44), 15810-15815.

91. Zlokovic, B. V. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. *Neuron*, 57(2), 178-201.